Revenue from operations declined 0.9% year-on-year to ₹143.6 crore from ₹156.3 crore.
The company’s Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) rose 93% year-on-year to ₹22.7 crore from ₹11.8 crore, while EBITDA margin improved to 14.8% from 7.6% in the year-ago period.
The board has recommended a final dividend of 30% of the face value of ₹5 each, translating to ₹1.50 per equity share for FY26, subject to shareholder approval at the upcoming annual general meeting.
Earlier, on May 7, The firm had said that it has received listing approvals from the National Stock Exchange of India and BSE for 20,79,409 equity shares of face value ₹5 each allotted pursuant to the conversion of warrants issued on a preferential basis.
The company said the shares were allotted following the exercise of options for conversion of convertible warrants into equity shares.
Also Read: Nasdaq futures jump nearly 1% as chip stocks rally, jobs data beats estimates
Ahead of the announcement of results, shares of Bajaj Healthcare Ltd ended marginally lower on May 8, with the stock settling at ₹338.45 on the NSE, down ₹1.25 or 0.37% from the previous close.
Also Read: India’s SEBI seeks feedback on revamp of share buyback rules
